In 1929, W E Dixon in his presidential address to the Section of Physiology of the British Association, endeavoured to show that: Gall precise knowledge in therapeutics is based upon controlled experiments on animals or man, and that the elucidation of the action of medicaments by the methods and data of experimental physiology is one of the most important steps taken to place medicine on a scientific basis.' While he would, without doubt, have welcomed the growth of clinical pharmacology as an independent scientific discipline, he would have been disappointed that forty years later Gold (1968) had to say: 'One cannot emphasize too strongly the fact that "clinical pharmacology" and "therapeutics" are two different disciplines. Clinical pharmacology is a science. Therapeutics could be, but, for the most part as it is pursued at the present time, it is not a science but a craft.'
In 1929, W E Dixon in his presidential address to the Section of Physiology of the British Association, endeavoured to show that: Gall precise knowledge in therapeutics is based upon controlled experiments on animals or man, and that the elucidation of the action of medicaments by the methods and data of experimental physiology is one of the most important steps taken to place medicine on a scientific basis.' While he would, without doubt, have welcomed the growth of clinical pharmacology as an independent scientific discipline, he would have been disappointed that forty years later Gold (1968) had to say: 'One cannot emphasize too strongly the fact that "clinical pharmacology" and "therapeutics" are two different disciplines. Clinical pharmacology is a science. Therapeutics could be, but, for the most part as it is pursued at the present time, it is not a science but a craft.' Dixon played an important role in the development of the concept of neurohumoral transmission, including observations on the action of adrenaline on the respiratory and cardiovascular systems. It may be appropriate, therefore, that this lecture in his memory is devoted to a consideration of the relationship between adrenergic activity and hyperthyroidism and anxiety, and to some therapeutic consequences of this relationship.
Hyperthyroidism
The relationship between sympathetic activity and hyperthyroidism has been recognized for more than a century, and resection of the cervical sympathetic chain was recommended in preference to thyroidectomy in elderly patients by Poncet in 1897, who claimed that it produced cardiac slowing and improvement in exophthalmos (Turner 1972a) . Evidence for such a relationship is the increased sensitivity to catecholamines seen in hyperthyroid patients both in the cardiovascular system (see Turner 1974) and also in other organs such as the iris (Turner 1 972b). Consistent with these observations is the reduction in many of the manifestations of experimental and spontaneous hyperthyroidism produced by adrenergic neurone-blocking drugs such as reserpine and guanethidine (see Turner 1974) . In 1948 Ahlquist suggested that the effects of adrenaline at peripheral sympathetic sites may be divided into two groups mediated by two classes of receptor, alpha and beta. The important alpha actions include vasoconstriction of arterioles in the skin and splanchnic region producing a rise in systemic blood pressure, inhibition of gut motility and pupillary dilatation. The beta actions, mimicked by the synthetic catecholamine isoprenaline, include increased rate and force of cardiac contraction, dilatation of arterioles supplying skeletal and coronary muscles, bronchial and uterine relaxation, and tremor.
The peripheral manifestations of hyperthyroidism are predominantly those which resemble beta receptor activity, and it seemed reasonable that treatment with selective beta receptor blockade would be preferable to general adrenergic blockade with neurone-blocking drugs.
Although Wilson et al. (1964) were unable to show that pronethalol, the first beta-adrenoceptor blocking drug to be studied clinically, produced Proc. roy. Soc. Med. Volume 69 May 1976 significant changes in hyperthyroid heart rate, cardiac output, or resting oxygen consumption, Turner et al. (1965) found that its successor, propanolol, produced a significant reduction in hyperthyroid tachycardia. Propranolol was further shown to reduce the rate of atrial fibrillation (Howitt & Rowlands 1966) and the amplitude of finger tremor in hyperthyroid patients (Marsden et al. 1967 ). The indications for beta adrenoceptor blockade in hyperthyroidism have been recently reviewed (Turner 1974 , Ramsay 1975 .
The discrepancy between the findings of Wilson et al. (1964) with pronethalol and those of other investigators with propranolol led Turner and his colleagues (Turner 1974) to seek significant doseresponse relationships in comparative studies between various beta-adrenoceptor blocking drugs on hyperthyroid tachycardia. They obtained such relationships with propranolol, sotalol and Ro 3-3528, but not with alprenolol, oxprenolol, pindolol or practolol. This second group of drugs differs from the first in possessing significant partial agonist or intrinsic sympathomimetic activity, arld Turner (1972a Turner ( , 1974 suggested that it is this activity, with the increased sensitivity to adrenoceptor stimulation seen in hyperthyroidism, which accounts for their lesser effectiveness in the treatment of this condition. Further evidence in support of this was the finding by Ramsay (1974) of a significant rise in urinary excretion of cyclic AMP in hyperthyroid patients treated with oxprenolol, but not with sotalol. On the other hand, Nelson & McDevitt (1975) have recently shown that oral propranolol and practolol could not be distinguished from each other in hyperthyroid patients in' their effects on palpitations, sweating, nervousness and tremor, even though the heart rate was reduced significantly more with propranolol than practolol. Final confirmation or otherwise of Turner's hypothesis is, therefore, still awaited.
Anxiety States While devising the protocol for the first study of propranolol in hyperthyroid tachycardia (Turner et al. 1965) , it was necessary to find a control group of patients who had similar increased heart rates but normal thyroid function. Patients with somatic anxiety states provided such a group, and it was observed that their responses to both alphaand beta-adrenoceptor blocking drugs and to amylobarbitone sodium were not significantly different from those of the hyperthyroid patients. Furthermore, some of the anxious patients claimed that they felt calmer following propranolol administration. Granville-Grossman & Turner (1966) therefore carried out a double-blind controlled cross-over trial in anxious patients and showed that propranolol was significantly better than placebo, but found on further analysis that it was the somatic symptoms of anxiety rather than the mental which were significantly improved by propranolol. This has been confirmed by other investigators (Wheatley 1969 , Tyrer & Lader 1974 . Evidence for the importance of betareceptor blockade came from a study by Bonn & Turner (1971) with D-propranolol which possesses negligible adrenoceptor blocking activity when compared with the commercially available racemic mixture, and which did not differ from placebo in anxious patients.
The question of whether the anxiolytic effects of propranolol are mediated by central or peripheral receptor blockade is still not settled. There is no doubt that beta-adrenoceptor blocking drugs have effects within the central nervous system, including fatigue, depression, insomnia and nightmares (Jefferson 1974) . However, the doses of propranolol used in anxiety are relatively small (up to 80 or 120 mg daily), and influence mainly its peripheral manifestations. Furthermore, Bonn et al. (1972) found that practolol, which has relatively low brain penetrance, was markedly effective in patients with prominent somatic anxiety.
Experimental studies in healthy volunteers to investigate the effects of beta-adrenoceptor blocking drugs on tests of central nervous function have yielded conflicting results. Glaister et al. (1973) detected significant impairment of performance in pursuit of rotor tests after intravenous oxprenolol 0.2 mg/kg, and Bryan et al. (1974) found significant impairment of hand-eye coordination and reaction time after oral propranolol 40 and 80 mg. Oh the other hand, a number of different studies with oxprenolol, propranolol and sotalol in doses up to 320 mg propranolol found no evidence of central nervous impairment in a variety of tests including EEG pursuit rotor, reaction time, critical flicker frequency, card sorting and symbol copying (Lader & Tyrer 1972 , Turner & Hedges 1973 , Ogle & Turner 1974 , Ogle, Markomihelakis & Turner 1974 . While the positive findings of Glaister et al. (1973) and Bryan et al. (1974) could have been due to sampling error, it is of interest that the tests in which these effects were seen involved complex motor responses to a stimulus. Bowman & Zaimis (1958) showed that beta-adrenoceptor stimulation produced an increase in rate of relaxation of slow and a decrease in that of fast skeletal muscle fibres in cats. Human skeletal muscle consists of a mixture of fast and slow fibres and Zaimis (1973) has suggested that stress-induced tremor in man could be due to circulating adrenaline acting on the slow fibres. Beta-adrenoceptor blockade in relatively low dosage blocks isoprenalineand adrenaline-induced tremors (Marsden et al. 1967) and also reduces senile and essential tremor Section ofMedicine, Experimental Medicine & Therapeutics 377 (Jefferson 1974) . It is possible, therefore, that beta-adrenoceptor blockade might interfere with the contraction of skeletal muscle fibres to impair reaction time, pursuit rotor and other coordination tests, in the presence of unaffected central nervous function. Variation in individual sensitivity to such effects might account for the different results in the tests which have been recorded.
The place of beta-adrenoceptor blockade in the treatment of anxiety is still being evaluated. New approaches to classification of anxiety states (Tyrer 1973 , Lader 1976a ) have distinguished patients with predominantly central or psychic anxiety where somatic complaints are of secondary importance, from somatic anxiety with prominent somatic manifestations, often in the cardiovascular system. Beta-adrenoceptor blockade would be expected to be particularly effective in the second group, and this was confirmed by Tyrer & Lader (1974) . However, the majority of patients with anxiety cannot be subdivided clearly into one of these two groups, as they have both central and somatic symptoms. Lader (1976b) has suggested that a combination of a centrally acting drug, such as benzodiazepine, in small dosage with a beta-adrenoceptor blocking -drug should, therefore, produce the maximum therapeutic advantage. This paper has attempted to demonstrate that relatively simple clinical pharmacological investigations, such as those based on the hypothesis of an association between adrenergic beta-receptor activity and hyperthyroidism and anxiety, can influence the therapeutic management of these conditions. Professor Turner's Dixon Memorial Lecture was presented at the last meeting of a course on Problem Areas in Cardiovascular Disease. Programmes for the earlier meetings were as follows: 
